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Reply to the Editor: 
We appreciate the comments of Drs. Hermansson, 
Konstantinov, and Aren in response to our article. 
Unfortunately, they have misread our conclusion, which 
may be summarized as follows: The case reports pre- 
sented raise concerns that the techniques of manipula- 
tion of malignant tissue during VATS procedures, 
regardless of the extent of resection, may lead to an 
increased rate of suture line occurrences; this increase 
is the result of inadequate tissue margins caused by an 
inability to palpate extent of disease. Furthermore, the 
reported cases raise concerns that disruption of tumor- 
bearing tissue with implantation within the pleural 
cavity or within chest wall incisions occurs at rates 
higher than seen during open thoracotomy and in- 
trathoracic resections. The technique they recommend 
of placing specimens into sealed bags before withdrawal 
from the chest is reasonable and may spare incisional 
contamination; however, this will not relieve concerns 
regarding inadequate margins or disruption within the 
pleural cavity. 
The morbidity and mortality of open procedures for 
the resection of intrathoracic malignant tumors are well 
documented in the literature, as is the previously 
vanishing rare problem of tumor implantation in an 
incision. Before VATS techniques are generally 
adopted, we advocate well-designed trials that will 
document both that VATS techniques are as safe as 
open techniques and that, stage for stage, VATS tech- 
niques provide 3- and 5-year survivals equal to or better 
than those achieved with open techniques. 
Robert J. Downey, MD 
Patricia McCormack, MD 
Division of Thoracic Surgery, 
Memorial Sloan-Kettering Cancer Center, 
New York, NY 10021 
Joseph LoCicero IlL MD 
Division of Thoracic Surgery 
New England Deaconess Hospital 
Boston, MA 02215 
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Effect of milrinone on coronary artery bypass 
grafts 
To the Editor." 
The effect of vasodilators on coronary artery bypass 
grafts is always an interesting topic because the vaso- 
constriction of the grafts may cause hypoperfusion 
syndrome, which may cause a serious problem in those 
who undergo coronary artery bypass with arterial 
grafts) 
With interest, I have read the article authored by Liu 
and associates a regarding the effect of a relatively new 
vasodilator, the phosphodiesterase II I inhibitor milri- 
none, which also possesses inotropic effects. In their 
study, the authors investigated the effect of milrinone in 
the human internal thoracic artery with regard to the 
vasorelaxant effect and the role of endothelium in such 
effect. Their findings in this article are similar to our 
previous reports in pharmacology journals. 3'4 In our 
reports, we have found that milrinone has vasorelaxant 
effects against all four vasoconstrictors we tested: po- 
tassium, U46619, phenylephrine, and endothelin-1. We 
have also tested the depressant effect of milrinone on 
the contraction induced by these vasoconstrictors. 3 In 
addition, we have found that the vasorelaxant effect of 
milrinone is endothelium independent)  I am glad to 
see that these results have been reconfirmed by Liu and 
his associates. Furthermore, we have discovered that 
milrinone and nitroglycerin have a synergistic effect 
that is clinically very important, because these two 
drugs are sometimes used together in the intensive care 
unit. 
However, on the basis of our findings with regard to 
the effect and the use of milrinone, we would emphasize 
three points: (1) Relaxation of milrinone in the potas- 
sium-precontracted internal thoracic artery is complete 
at the highest concentration ( -4  log M), although the 
sensitivity to this agent is lower (less potent) than to the 
other three agents. This demonstrates the selectivity of 
the vasorelaxant effect of this vasodilator. (2) The 
inhibitory effect of milrinone in the contraction induced 
by the four important vasoconstrictors is also slightly 
selective. It was more potent in inhibition of the 
receptor-mediated (by endothelin-1 and phenyleph- 
rine) than the depolarizing agent potassium-mediated 
contraction (Fig. 1). This is shown by the more signifi- 
cant suppression effect in the contraction induced by 
endothelin-1 and phenylephrine) (3) There is a syner- 
gistic vasorelaxant effect of the phosphodiesterase II I 
inhibitor milrinone and the nitrovasodilator nitroglyc- 
erin in human conduit arteries. This effect may be 
beneficial to patients undergoing coronary artery bypass 
grafting and to other patients requiring these vasodila- 
tors. Reduced doses of the vasodilators may be suffi- 
cient to produce vasodilatation similar to that produced 
by either of them alone at higher concentrations (Fig. 
2) .4 
On the basis of this information, we would suggest 
clinical considerations and indications for the use of 
milrinone after coronary artery bypass grafting as fol- 
lows: 
1. The use of milrinone is best indicated when the 
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Fig. 1. Mean concentration (-log M)-contraction (percentage of 100 mmol/L K+-induced contraction) curves 
for endothelin-1. Three rings obtained from each patient were allocated to each treatment. One ring was the 
control (O) without pretreatment of milrinone. For the other two rings, milrinone 7/xmol/L (©) or 70 (A) 
/xmol/L was added into the organ bath 10 minutes before the start of the endothelin-1 curve. Symbols represent 
data averaged from six rings (from six patients). Vertical error bars are i standard error of mean values. **p < 
0.01, analysis of variance among the three groups and Scheffe's F test compared with the control at the maximal 
contraction. MiI, Milrinone. (From He and Yang. Inhibition of Vasoconstriction by Phosphodiesterase III 
Inhibitor Milrinone in Human Conduit Arteries Used as Coronary Bypass Grafts. J Cardiovasc Pharmacol 
1996;28:208:14; published with permission of Lippincott-Raven Publishers, Philadelphia, Pa.) 
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Fig. 2. Relaxation induced by milrinone 3/xmol/L (O, n = 5), nitroglycerin 10 nmol/L (©, n = 5), or a 
combination of the two (A, n = 6) in the human internal thoracic artery prec0ntracted by potassium 
chloride (K +, 25 mmol/L). & EA +B, Theoretic overadditive curve (see reference 4). *p < 0.05 compared 
with nitroglycerin and theoretic urve. Vertical error bars are ! standard error of mean values. Mil, 
Milrinone; GTN, nitroglycerin. (From He, Yang, Gately, et al. Potential Greater Than Additive 
Vasorelaxant Actions of Milrinone and Nitroglycerin on Human Conduit Arteries. Br J Clin Pharmacol 
1996;41:101-7; published with permission of Blackwell Science Ltd., Oxford, United Kingdom.) 
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patient requires vasodilatation as well as inotropic sup- 
port. 
2. If an arterial graft is suspected to be in spasm or the 
patient has symptoms of hypoperfusion syndrome, possi- 
bly caused by graft constriction (manifested by low cardiac 
output, left ventricular failure, rising pulmonary wedge 
pressure, and hypotensionl), milrinone may be given as a 
vasodilator in combination with other therapies in an 
attempt to dilate the possibly constricted graft or coronary 
artery. It is particularly indicated when other traditional 
vasodilators uch as nitroglycerin have been used and 
found to be of little help: In this situation, milrinone is 
probably well indicated because tolerance to nitroglycerin 
is suspected. 
3. When milrinone is used in combination with nitro- 
glycerin, these two vasodilators may have a synergistic 
vasorelaxant effect. Reduced doses of the vasodilators 
may be sufficient to obtain the desirable vasorelaxant 
effect either in bypass grafts or in the systemic (or 
coronary) circulation. 
Guo-Wei He, MD, PhD 
Professor of Cardiothoracic Surgery 
The University of Hong Kong 
Grantham Hospital 
125 Wong Chuk Hang Road 
Aberdeen, Hong Kong 
REFERENCES 
1. Loop FD, Thomas JD. Hypoperfusion after arterial bypass 
grafting. Ann Thorac Surg 1993;56:812-3. 
2. Liu JJ, Doolan LA, Xie B, Chen JR, Buxton BF. Direct 
vasodilator effect of milrinone, an inotropic drug, on arterial 
coronary bypass grafts. J Thorac Cardiovasc Surg 1997;113: 
108-13. 
3. He G-W, Yang C-Q. Inhibition of vasoconstriction byphos- 
phodiesterase III inhibitor milrinone in human conduit arter- 
ies used as coronary bypass grafts. J Cardiovasc Pharmacol 
1996;28:208-14. 
4. He G-W, Yang C-Q, Gately H, et al. Potential greater than 
additive vasorelaxant actions of milrinone and nitroglycerin on 
human conduit arteries. Br J Clin Pharmacol 1996;41:101-7. 
12/8/82352 
Hyperoxic cardiopuimonary bypass causes 
reoxygenation injury and lipid peroxidation 
To the Editor: 
With great interest I read the brief communication 
"Contribution of Hyperoxia to Lipid Peroxidation in 
Coronary Artery Operations: Should We Keep a Low 
Oxygen Tension?" by Hadjinikolaou and colleagues (J 
Thorac Cardiovasc Surg 1997;113:212-3). However, I have 
to disagree with several of their statements. 
First, the comment hat "the contribution of hyper- 
oxia to oxygen free radical generation and consequent 
lipid peroxidation in cardiac operations has to date not 
been addressed" is wrong. We intensively studied the 
effect of hyperoxic ardiopulmonary bypass (CPB) on 
oxygen-derived free radical-induced lipid peroxidation in 
hypoxic immature hearts I-4' 6 and in normoxic adult hearts. 5 
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Fig. 1. Malondialdehyde (MDA) as a measure of lipid 
peroxidation from systemic venous blood at the start and 
end of CPB. The hyperoxic group included 10 patients 
during coronary artery bypass graft operations in which 
CPB was conducted in a hyperoxic fashion (Po 2 = 450 mm 
Hg). The normoxic group consisted of 10 patients also 
undergoing coronary artery bypass graft operations in 
which CPB was run with reduced oxygen levels (Po 2 150 
mm Hg). The groups did not differ in terms of age, sex, 
severity of disease, contractility, number of grafts, length 
of CPB, or ischemic time. *p < 0.05 versus hyperoxic 
group (analysis of variance). 
The results show that hyperoxic CPB causes reoxygen- 
ation damage, leading to lipid peroxidation, reduced 
antioxidant reserve capacity, creatine kinase release, 
and impaired postbypass contractility in hypoxic imma- 
ture hearts. I-e' 6 Reports by other groups also address 
the issue] Additionally, in normoxic adult hearts, hy- 
peroxic CPB causes lipid peroxidation, creatine kinase 
and lactate dehydrogenase r lease, and an increase in 
polymorphonuclear leukocyte lastase. 5 
Second, the authors further state that lipid peroxida- 
tion is absent during CPB. Additionally, they did not 
find a relationship between the degree of hyperoxia nd 
levels of lipid peroxidation. The results of our studies 
clearly indicate the existence of lipid peroxidation as 
early as 5 minutes after the start of CPB. We measured 
conjugated ienes as a marker of lipid peroxidation. 
Compared with results in control subjects without hy- 
poxia, hyperoxic CPB (oxygen tension [Po2] = 400 mm 
Hg) caused a 13-fold increase in myocardial conjugated 
diene production during cardioplegic induction (5 min- 
utes after the start of CPB) in hypoxic immature 
hearts.Z, 3 Reduction of Po2 during CPB to normoxic 
levels (100 mm Hg) resulted in significantly (73%) 
2 3 lower production of myocardial conjugated ienes. " 
Furthermore, for the first time, we described a new 
